Entrada Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€68.59M - Cost of goods sold
€1.73M - Gross profit
€66.01M - SG&A expenses
€35.41M - R&D expenses
€115.32M - EBITDA
-€81.32M - D&A
€1.67M - EBIT
-€82.99M - Interest expenses
€0.00 - EBT
-€66.37M - Tax expenses
-€3.07M - Net income
-€63.31M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€21.90M - Changes in working capital
-€42.06M - Operating cash flow
-€106.90M - Capex
€2.32M - Other investing cash flow
€0.00 - Net investing cash flow
€7.78M - Total cash dividends paid
€0.00 - Issuance of common stock
-€338.31K - Debt repayment
€0.00 - Other financing cash flow
€1.84M - Net financing cash flow
€1.79M - Foreign exchange effects
€0.00 - Net change in cash
-€97.33M - Cash at end of period
€65.96M - Free cash flow
-€104.58M
Balance sheet
- Cash and cash equivalents
€62.55M - Cash and short-term investments
€305.53M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€13.06M - Total current assets
€318.59M - Property, plant & equipment
€65.15M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€3.58M - Total non-current assets
€68.73M - Total assets
€387.32M - Accounts payable
€1.60M - Short-term debt
€4.71M - Other current liabilities
€13.82M - Total current liabilities
€17.09M - Long-term debt
€42.53M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€167.43K - Total non-current liabilities
€42.70M - Total liabilities
€59.79M - Common stock
€3.45K - Retained earnings
-€163.80M - Other equity
€345.21K - Total equity
€327.53M - Total liabilities and shareholders' equity
€387.32M
Company information
- Market capitalization
€223.69M - Employees
183 - Enterprise Value
€288.99M
Company ratios
- Gross margin
-
96.2% Much better than peer group: -155,429,222,103,272.1% - EBITDA margin
-
-118.6% Much better than peer group: -854,654,030,832,827.5% - EBIT margin
-
-121.0% Much better than peer group: -862,632,578,553,032.5% - EBT margin
-
-96.8% Much better than peer group: -861,608,911,683,767.0% - Net margin
-
-92.3% Much better than peer group: -861,608,911,685,265.6% - ROE
-
-19.3% Even with peer group: -21.1% - ROA
-
-16.3% Better than peer group: -35.6% - Asset turnover
-
17.7% Better than peer group: 2.1% - FCF margin
-
-159.2% Much better than peer group: -717,908,829,460,854.4% - FCF yield
-48.8% - Efficiency ratio
218.6% - Net sales per employee
-
€374.81K - Net income per employee
-
-€345.94K